Across TCGA pan-cancer cohorts, C19orf71 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated C19orf71 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher C19orf71 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C19orf71 expression acts as an unfavorable survival marker.
ESCA are the cancer types where C19orf71 Mutation most reproducibly stratifies survival.